Ayala Pharmaceuticals Inc (ADXS)

[Gantor50]

Hornet, I am in agreement with your arguments about the importance of cost controls. In fairness I think it does seem Lombardo has started to make changes to better control costs, but so much damage has already been done. Is he doing enough?

The recent news that ADXS hired a company whose findings suggested they were under compensated still makes me wonder if they get it. In the real pharma world wage increases are frozen and bonuses are impacted when milestones and targets are not hit. Even beyond that there is no way in the real pharma world that this BOD would remain unchallenged and unchanged after what they have allowed on their watch.

And while I am happy that Lombardo has started to try and control costs somewhat, they appear to be doing it largely by shutting down research and development in areas farthest from commercialization.

While that makes practical sense, it isn't ideal for a Biotech built on R&D to have to stop or slow down R&D in order to cut costs. I get the pragmatism based on the current circumstances, but in my opinion this is another reason why ADXS needs to sell itself so it can get the science in the hands of a better funded Big Pharma who can finance the required R&D needed to get multiple indications to market in parallel.